Morpholinos

Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition

Volumn , Issue , 2007, Pages 565-582

  Iversen, Patrick L ^a  

^a AVI BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85002982666     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (79)

1. Giles RV, Spiller DG, and Tidd DM (1993) Chimeric oligodeoxynucleotide analogues: Enhanced cell uptake of structures which direct RNase H with high specificity. Anti-Cancer Drug Des. 8: 3-51.
2. Stein D, Foster E, Huang SB, Weller D, and Summerton J (1997) A specificity comparison of four antisense types: morpholino, 2′-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev. 7: 151-157.
3. Burgess TL, Fisher EF, Ross SL, Bready JV, Qian YX, Bayewitch LA, Cohen AM, Herrera CJ, Kramer TB, Lott FD, Martin FH, Pierce GF, Simoner L, and Farrell CL (1993) The antiproliferative activity of c-myb and c-myc antisense oligonucleotides is smooth muscle cells iscaused by a nonantisense mechanism. Proc. Natl. Acad. Sci. USA 92: 4051-4055.
4. Hudziak RM, Summerton J, Weller, DD, and Iversen PL (2000) Antiproliferative effects of steric blocking phosphorodiamidate morpholino antisense agents directed against c-myc. Antisense Nucleic Acid Drug Dev. 10: 163-176.
5. Copple BL, Gmeiner WM, and Iversen PL (1995) Reaction between metabolically activated acetaminophen and phosphorothioate oligonucleotides. Toxicol. Appl. Pharmacol. 133: 53-63.
6. Cornish KG, Iversen PL, Smith LJ, Arneson MA, and Bayever E (1993) Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey. Pharmacol. Commun. 3: 239-247.
7. Iversen PL, Cornish KG, Iversen LJ, Mata JE, and Bylund DB (1999) Bolus intravenous injection of phosphorothioate oligonucleotides causes severe hypotension by acting as 1-adrenergic receptor antagonists. Toxicol. Appl. Pharmacol. 160: 289-296.
8. Mata JE, Bishop MR, Tarantolo SR, Angle CR, Swanson SA, and Iversen PL (1999) Evidence of enhanced iron excretion during systemic phosphorothioate oligodeoxynucleotide treatment. J. Toxicol. Clin. Toxicol. 38(4): 383-387.
9. Farman CA and Kornbrust DJ (2003) Oligodeoxynucleotide studies in primates: antisense and immune stimulatory indications. Toxicol. Pathol. (Jan-Feb) 31(suppl.): 119-122.
10. Webb MS, Tortora N, Cremese M, Kozlowska H, Blaquiere M, Devine DV, and Kornbrust DJ (2001) Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys. Antisense Nucleic Acid Drug Dev. (Jun) 11(3): 155-163.
11. Levin AA (1999) A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta 1489(1): 69-84.
12. Henry SP, Novotny W, Leeds J, Auletta C, and Kornbrust DJ (1997) Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev. (Oct) 7(5): 503-510.
13. Stein CA and Cheng YC (1993) Antisene oligonucleotides as therapeutic agents-Is the bullet really magical? Science 261: 1004-1012.
14. Stein CA (1995) Does antisense exist? Nat. Med. 1: 1119-1121.
15. Shoeman RL, Hartig SB, Huang Y, Grub S, and Traub P (1997) Fluorescence microscopic comparison of the binding of phosphodiester and phosphorothioate (antisense) oligodeoxyribonucleotides to subcellular structures, including intermediate filaments, the endoplasmic reticulum, and the nuclear interior. Antisense Nucleic Acid Drug Dev. 7: 291-298.
16. Hudziak RM, Barofsky E, Barofsky DF, Weller DL, Huang SB, and Weller DD (1996) Resistance of Morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acids Drug Dev. 6: 267-272.
17. Ricker JL, Mata JE, Iversen PL, and Gattone VH (2002) c-myc Antisense oligonucleotide treatment ameliorates murine infantile polycystic kidney disease. Kidney Int. 61: S125-S131.
18. Arora V, Knapp DC, Smith BL, Statdfield ML, Stein DA, Reddy MT, Weller DD, and Iversen PL (2000) c-Myc antisense limits rat liver regeneration and indicates role for c-myc in regulating cytochrome P-450 3A activity. J. Pharmacol. Exp. Ther. 292: 921-928.
19. Kipshidze N, Keane E, Stein D, Chawla P, Skrinska V, Shankar LR, Khanna A, Komorowski R, Haudenschild C, Iversen P, Leon M, Keelan MH, and Moses J (2001) Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheterization Cardiovasc. Interventions 54: 247-256.
20. Kipshidze NN, Kim H-S, Iversen PL, Yazdi HA, Bhargava B, Mehran R, Haundenschild C, Dangas G, Stone GW, Roubin GS, Leon MB, and Moses JW (2002) Intramural delivery of advanced antisense oligonucleotides with infiltrator cathetor inhibits c-myc expression and intimal hyperplasia in the porcine. J. Am. Coll. Cardiol. 39(10): 1686-1691.
21. London CA, Sekhon HS, Arora V, Stein DA, Iversen PL, and Devi GR (2003) A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell cinvasion and tumorigenicity. Cancer Gene Ther. 10: 823-832.
22. Arora V, Hannah TL, Iversen PL, and Brand RM (2002) Transdermal use of phosphorodiamidate morpholino oligomer AVI-4472 inhibits cytochrome P450 3A2 activity in male rats. Pharmaceut. Res. 19(10): 1465-1470.
23. Qin G, Taylor M, Ning YY, Iversen P, and Kobzik L (2000) In vivo evaluation of a morpholino antisense oligomer directed against TNF. Antisense Nucleic Acid Drug Dev. 10: 11-16.
24. Arora V, Knapp DC, Reddy MT, Weller DD, and Iversen PL (2002) Phosphorodiamidate morpholino oligomers demonstrate antisense activity in rat liver following oral administration. J. Pharm. Sci. 91(4): 1009-1018.
25. Ghosh C, Reddy M, and Iversen PL (2003) Analysis of antisense phosphorodiamidate morphino oligomer teratogenicity in the zebrafish embryogenesis model. Anal. Pharmacol. 1(3): 80-89.
26. Iversen PL and Newbury S (2005) Manipulation of zebrafish embryogenesis by phosphorodiamidate morpholino oligomers indicates minimal non-specific teratogenesis. Curr. Opin. Mol. Ther. 7(2):104-108.
27. Arora V, Devi GR, and Iversen PL (2004) Neutrally charged phosphorodiamidate morpholino oligomers: uptake, efficacy and pharmacokinetics. Curr. Pharm. Biotech. 5(5): 431-439.
28. Stein D, Skilling D, Iversen PL, and Smith AO (2001) Inhibition of Vesivirus infections in mammalian tissue culture with antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev. 11: 317-325.
29. Deas TS, Binduga-Gajewska I, Tilgner M, Ren P, Stein DA, Moulton HM, Iversen PL, Kauffman EB, Kramer LD, and Shi P-Y (2005) Inhibition of Flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J. Virol. 79(8): 4599-4609.
30. Kinney RM, Huang CY-H, Rose BC, Kroeker AD, Dreher TW, Iversen PL, and Stein DA (2005) Inhibition of dengue virus serotypes 1 to 4 in cell culture with morpholino oligomers. J. Virol. 79(8):5116-5128.
31. Holden KL, Stein DA, Pierson TC, Ahmed AA, Clyde K, Iversen PL, and Harris E (2005) Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the terminal 3′ stem-loop structure. Virology 344: 439-452.
32. van den Born E, Stein DA, Iversen PL, and Snijder EJ (2005) Antiviral activity of morpholino oligomers designed to block various aspects of Equine arteritis virus amplification in cell culture. J. Gen. Virol. 86(11): 3081-3090.
33. Zhang YJ, Stein DA, Fan SM, Wang KY, Kroeker AD, Meng XJ, Iversen PL, and Matson DO (2006) Suppression of porcine reproductive and respiratory syndrome virus replication by morpholino antisense oligomers. Vet. Microbiol. (in press).
34. Neuman BW, Stein DA, Kroeker AD, Paulino AD, Moulton HM, Iversen PL, and Buchmeier MJ (2004) Antisense morpholino oligomers directed against the 5′-end of the genome inhibit coronavirus proliferation and growth. J. Virol. 78(11): 5891-5899.
35. Neuman BW, Stein DA, Kroeker AD, Churchill MJ, Kim AM, Dawson P, Moulton HM, Bestwick RK, Iversen PL, and Buchmeier MJ (2005) Inhibition, escape and attenuation of SARS coronavirus treated with antisense morpholino oligomers. J. Virol. 79: 9665-9676.
36. Warfield KL, Swenson DL, Olinger GG, Nichols DK, Pratt WD, Blouch R, Stein DA, Aman MJ, Iversen PL, and Bavari S (2006) Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathogens 2(1): 1-9.
37. Enterlein S, Warfield KL, Swenson DL, Stein DA, Smith JL, Gamble CS, Kroeker AD, Iversen PL, Bavari S, and Muhlberger K (2006) VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob. Agents Chemother. 50(3): 984-993.
38. Alonso M, Stein DA, Thomann E, Moulton H, Leong J-AC, Iversen P, and Mourich D (2005) Inhibition of infectious hematopoietic necrosis virus in cell cultures with peptide-conjugated morpholino oligomers J. Fish Disease 28: 399-410.
39. Ge Q, Kroeker AD, Bestwick RK, Iversen PL, Chen J, and Stein D (2006) Inhibition of influenza A virus in Vero cell culture with morpholino oligomers. J. Virol. (in press).
40. Zhang YJ, Wang KY, Stein DA, Patel D, Watkins R, Moulton HM, Iversen PL, and Matson DO (2006) Inhibition of replication and transcription activator and latency-associated nuclear antigen of Kaposi’s sarcoma-associated herpesvirus by morpholino oligomers. Antivir. Res. 73: 12-23.
41. Geller BL, Deere JD, Stein DA, Kroeker AD, Moulton HM, and Iversen PL (2003) Inhibition of gene expression in Escherichia coli by antisense phosphorodiamidate morpholino oligomers. Antimicrob. Agents Chemother. 47: 3233-3239.
42. Deere J, Iversen P, and Geller BL (2005) Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in Escherichia coli. Antimicrob. Agents Chemother. 49: 249-255.
43. Geller BL, Deere J, Tilley L, and Iversen PL (2005) Antisense phosphorodiamidate morpholino oligomer inhibits viability of Escherichia coli in pure culture and in mouse peritonitis. J. Antimicrob. Chemother. 10: 1093.
44. Tilley LD, Hine OS, Kellogg JA, Hassinger JN, Weller DD, Iversen PL, and Geller BL (2006) Genespecific effects of antisense phosphorodiamidate morpholino oligomer-peptide conjugates on Escherichia coli and Salmonella enterica Serovar Typhimurium in pure culture and in tissue culture. Antimicrob. Agents Chemother. 50(8): 2789-2796.
45. Simonsen M (2003) Changing role for cardiac surgery as use of stents continues growth. Cardiovasc. Device Update 9: 1-7.
46. Topol EJ and Serruys PW (1998) Frontiers in interventional cardiology. Circulation 98: 1802-1820.
47. Serruys PW, Foley DP, Suttorp M-J, Rensing BJ, Suryapranta H, Materne P, van den Bos A, Benit E, Anzuini A, Rutsch W, Legrand V, Dawkins K, Cobaugh M, Bressers M, Backx B, Wijns W, and Colombo A (2002) A randomized comparison of the value of additional stenting after optimal balloon angioplasty for long coronary lesions. J. Am. Coll. Cardiol. 39: 393-399.
48. van den Brand M, Rensing J, Morel MM, Foley DP, de Valk V, Breeman A, Suryapranata H, Haalebos MM, Wijns W, Wellens F, Balcon R, Magee P, Rigeiro E, Buffolo E, Unger F, and Serruys PW (2002) The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. J. Am. Coll. Cardiol. 39: 559-564.
49. Nakatani M, Takeyama Y, Shibata M, Yorozuya M, Suzuki M, Koba S, and Katagirl T (2003) Mechanisms of restenosis after coronary intervention. Difference between plain old balloon angioplasty and stenting. Cardiovasc. Pathol. 12: 40-48.
50. Goldberg SL, Loussararian A, De Gregorio J, Di Mario C, Albierro R, Colombo A (2001) Predictors of diffuse and aggressive intrastent restenosis. J. Am. Coll. Cardiol. 37: 1019-1025
51. Kipshidze N, Keane E, Stein D, Chawla P, Skrinska V, Shankar LR, Khanna A, Komorowski R, Haudenschild C, Iversen P, Leon M, Keelan MH, and Moses J (2001) Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter. Cardiovasc. Interventions 54: 247-256.
52. Kipshidze N, Iversen P, Keane E, Stein D, Chawla P, Skrinska V, Shankar LR, Mehran R, Chekanov V, Dangas G, Komorowski R, Haudenschild C, Khanna A, Leon M, Keelan MH, and Moses J (2002) Complete vascular healing and sustained suppression of neointimal thickening after local delivery of advanced c-myc antisense at six months follow-up in a rabbit balloon injury model. Cardiovasc. Radiation Med. 3: 26-30.
53. Kipshidze NN, Kim H-S, Iversen PL, Yazdi HA, Bhargava B, Mehran R, Haundenschild C, Dangas G, Stone GW, Roubin GS, Leon MB, and Moses JW (2002) Intramural delivery of advanced antisense oligonucleotides with infiltrator cathetor inhibits c-myc expression and intimal hyperplasia in the porcine. J. Am. Coll. Cardiol. 39(10): 1686-1691.
54. Kipshidze NN, Iversen PL, Kim H-S, Yazdi HA, Dangas G, Seaborn R, New G, Tio FB, Waxman R, Mehran R, Tsapenko M, Stone GW, Roubin GS, Iyer S, Leon MB, and Moses JW (2004) Advanced c-myc antisense (AVI-4126)-eluting phosphrylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model. Catheter. Cardiovasc. Interventions 61: 518-527.
55. Porter TR, Xie F, Knapp D, Iversen P, Markey LA, Tsutsui JM, Maiti S, Lof J, Radio SJ, and Kipshidze N (2006) Targeted vascular delivery of antisense molecules using intravenous microbubbles. Cardiovasc. Revasc. Med. 7(1): 25-33.
56. Kipshidze NN, Tsapenko M, Iversen P, and Burger D (2005) Antisense therapy for restenosis following percutaneous coronary intervention. Expert Opin. Biol. Ther. 5(1): 79-89.
57. Knapp DC, Mata JE, Reddy MT, Devi GR, and Iversen PL (2003) Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in Lewis lung carcinoma model. Anti-cancer Drugs 14(1): 39-47.
58. Iversen PL, Arora V, Acker AJ, Mason DH, and Devi, GR (2003) Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft model and a phase I safety study in humans. Clin. Cancer Res. 9: 1-10.
59. Devi GR, Oldencamp JR, London CA, and Iversen PL (2002) Inhibition of human chorionic gonadotropin-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells. The Prostate 53(3): 200-210.
60. London CA, Sekhon HS, Arora V, Stein DA, Iversen PL, and Devi GR (2003) A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell cinvasion and tumorigenicity. Cancer Gene Ther. 10: 823-832.
61. Roy HK, Iversen PL, Hart J, Liu Y, Koetsier JL, Kim Y, Kunte DP, Madugula M, Backman V, and Wali RK (2004) Down-regulation of SNAIL suppresses MIN mouse tumorigenesis: modulation of apoptosis, proliferation and fractal dimension. Mol. Cancer Ther. 3(9): 1159-1165.
62. Amantana A, London CA, Iversen PL, and Devi GR (2004) X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol. Cancer Ther. 3(6): 699-707.
63. Ko YJ, Devi GR, London CA, Kayas A, Iversen PL, Bubley GJ, and Balk, SP (2004) Antisense mediated androgen receptor downregulation in prostate cancer xenografts J. Urol. 172: 1140-1144.
64. Devi GR, Beer TM, Corless CL, Arora V, Weller DL, and Iversen PL (2005) In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin. Cancer Res. 11(10): 3930-3938.
65. Arora V and Iversen PL (2001) Redirection of drug metabolism using antisense technology. Curr. Opin. Mol. Therap. 3(3): 249-257.
66. Desjardins JP and Iversen PL (1995) Inhibition of the rat cytochrome P450 3A2 by an antisense phosphorothioate oligodeoxynucleotide in vivo. J. Pharm. Exp. Ther. 275(3): 1608-1613.
67. Arora V (2003) Antisense strategies for redirection of drug metabolism using paclitaxel as a model. In Methods in Molecular Medicine, Vol. 106: Antisense Therapeutics, Second Edn., I. Phillips, ed., Humana Press Inc., Totowa, NJ.
68. Mahadevan B, Arora V, Schild LJ, Keshava C, Cate M, Iversen PL, Poirier M, Weston A, Pereira C, and Baird WM (2005) Reduction in tamoxifen-induced CYP3A2 expression and DNA adducts using antisense technology. Mol. Carcinogenesis, Dec 3.
69. Arora V, Hannah TL, Iversen PL, and Brand RM (2002) Transdermal use of phosphorodiamidate morpholino oligomer AVI-4472 inhibits cytochrome P450 3A2 activity in male rats. Pharmaceut. Res. 19(10): 1465-1470.
70. Arora V, Knapp DC, Reddy MT, Weller DD, and Iversen PL (2002) Phosphorodiamidate morpholino oligomers demonstrate antisense activity in rat liver following oral administration. J. Pharm. Sci. 91(4): 1009-1018.
71. Arora V, Cate M, Ghosh C, and Iversen PL (2002) Phosphorodiamidate morpholino oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. Drug Metabol. Dispos. 30(7): 1-6.
72. Wilton SD, Lloyd F, Carville K, Fletcher S, Honeyman K, Agrawal S, and Kole R (1999) Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscular Disord. 9: 330-338.
73. Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, and Wilton SD (2006) Dystrophin expression in the mdx mouse after localized and systemic administration of a morpholino antisense oligonucleotide. J Gene Med. 8: 207-216.
74. McClorey G, Moulton HM, Iversen PL, Fletcher S, and Wilton SD (2006) Antisense oligonucleotideinduced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther. (Epub ahead of print).
75. McClorey G, Fall AM, Moulton HM, Iversen PL, Rasko JE, Ryan M, Fletcher S, and Wilton SD (2006) Induced dystrophin exon skipping in human muscle explants. Neuromuscular Disord. 16: 1-8.
76. Fall AM, Johnsen R, Honeyman K, Iversen P, Fletcher S, and Wilton SD (2006) Induction of revertant fibers in the mdx mouse using antisense oligonucleotides. Genetic Vaccines Ther. 4: 3-15.
77. Nelson MH, Stein DA, Kroeker AD, Hatlevig SA, Iversen PL, and Moulton HM (2005) Arginine-rich peptide conjugation of morpholino oligomers: effects on antisense activity and specificity. Bioconjugate Chem. 16: 959-966.
78. Moulton, HM, Hase HC, Smith KH, and Iversen PL (2003) HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev. 13: 32-37.
79. Moulton HM, Nelson MH, Hatlevig SA, Reddy MT, and Iversen PL (2004) Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. BioConjugate Chem. 15(2):290-299.